[go: up one dir, main page]

SG10202002458PA - Process for manipulating the level of glycan content of a glycoprotein - Google Patents

Process for manipulating the level of glycan content of a glycoprotein

Info

Publication number
SG10202002458PA
SG10202002458PA SG10202002458PA SG10202002458PA SG10202002458PA SG 10202002458P A SG10202002458P A SG 10202002458PA SG 10202002458P A SG10202002458P A SG 10202002458PA SG 10202002458P A SG10202002458P A SG 10202002458PA SG 10202002458P A SG10202002458P A SG 10202002458PA
Authority
SG
Singapore
Prior art keywords
glycoprotein
manipulating
level
glycan content
glycan
Prior art date
Application number
SG10202002458PA
Inventor
Daniel R Leiske
Michael T Trentalange
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55024253&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG10202002458P(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of SG10202002458PA publication Critical patent/SG10202002458PA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/775—Apolipopeptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C07K16/242—Lymphotoxin [LT]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/005—Glycopeptides, glycoproteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/05—Inorganic components
    • C12N2500/10—Metals; Metal chelators
    • C12N2500/20—Transition metals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/60—Buffer, e.g. pH regulation, osmotic pressure
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2523/00—Culture process characterised by temperature

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
SG10202002458PA 2014-12-01 2015-12-01 Process for manipulating the level of glycan content of a glycoprotein SG10202002458PA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462085759P 2014-12-01 2014-12-01

Publications (1)

Publication Number Publication Date
SG10202002458PA true SG10202002458PA (en) 2020-04-29

Family

ID=55024253

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10202002458PA SG10202002458PA (en) 2014-12-01 2015-12-01 Process for manipulating the level of glycan content of a glycoprotein
SG11201704351WA SG11201704351WA (en) 2014-12-01 2015-12-01 Process for manipulating the level of glycan content of a glycoprotein

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG11201704351WA SG11201704351WA (en) 2014-12-01 2015-12-01 Process for manipulating the level of glycan content of a glycoprotein

Country Status (22)

Country Link
US (5) US10167492B2 (en)
EP (2) EP3680344A1 (en)
JP (4) JP6698681B2 (en)
KR (1) KR102623965B1 (en)
CN (1) CN107109455B (en)
AU (4) AU2015355087B2 (en)
CA (1) CA2969225C (en)
CL (1) CL2017001369A1 (en)
CY (1) CY1123247T1 (en)
DK (1) DK3227454T3 (en)
EA (2) EA036178B1 (en)
ES (1) ES2784503T3 (en)
HU (1) HUE049201T2 (en)
IL (2) IL276165B (en)
LT (1) LT3227454T (en)
MX (1) MX385409B (en)
PL (1) PL3227454T3 (en)
PT (1) PT3227454T (en)
SG (2) SG10202002458PA (en)
SI (1) SI3227454T1 (en)
WO (1) WO2016089919A1 (en)
ZA (2) ZA201703729B (en)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2015355087B2 (en) 2014-12-01 2020-04-09 Amgen Inc. Process for manipulating the level of glycan content of a glycoprotein
US11719704B2 (en) 2015-12-30 2023-08-08 Momenta Pharmaceuticals, Inc. Methods related to biologics
EP3596225A1 (en) * 2017-03-14 2020-01-22 Amgen Inc. Control of total afucosylated glycoforms of antibodies produced in cell culture
CN110520538B (en) * 2017-03-31 2024-02-20 勃林格殷格翰国际公司 Perfusion medium
CN111373028B (en) * 2017-11-30 2022-07-05 正大天晴药业集团南京顺欣制药有限公司 Method for producing protein
BR112020019559A2 (en) * 2018-03-26 2021-01-12 Amgen Inc. TOTAL AFUCOSYLATED GLYCOFORMS OF ANTIBODIES PRODUCED IN CELL CULTURE
AU2019274782A1 (en) * 2018-05-24 2020-12-03 Ares Trading S.A. Method for controlling the afucosylation level of a glycoprotein composition
CA3099757A1 (en) 2018-06-05 2019-12-12 Amgen Inc. Modulating antibody dependent cellular phagocytosis
WO2020055900A1 (en) 2018-09-11 2020-03-19 Amgen Inc. Methods of modulating antibody-dependent cell-mediated cytotoxicity
HU231514B1 (en) 2018-11-07 2024-07-28 Richter Gedeon Nyrt. Method for modifying the glycosylation profile of a recombinant glycoprotein produced in cell culture
ES2994759T3 (en) 2018-11-13 2025-01-30 Janssen Biotech Inc Control of trace metals during production of anti-cd38 antibodies
CN113474366B (en) * 2018-12-31 2025-01-17 动量制药公司 Methods of producing ustekinumab
WO2020160133A1 (en) * 2019-01-30 2020-08-06 Amgen Inc. Aflibercept attributes and methods of characterizing and modifying thereof
WO2020227726A1 (en) 2019-05-06 2020-11-12 Amgen Inc. Modulating antibody effector functions
JP2020188737A (en) * 2019-05-23 2020-11-26 東ソー株式会社 Production method of antibody with improved antibody dependent cell mediated cytotoxicity activity
KR20220069982A (en) 2019-09-26 2022-05-27 암젠 인크 Methods for producing antibody compositions
US20230287335A1 (en) * 2020-07-30 2023-09-14 Amgen Inc. Cell culture media and methods of making and using the same
US20230313259A1 (en) * 2020-08-14 2023-10-05 Bristol-Myers Squibb Company Manufacturing process for protein
MX2023004364A (en) 2020-10-15 2023-05-03 Amgen Inc Relative unpaired glycans in antibody production methods.
WO2022261021A1 (en) 2021-06-07 2022-12-15 Amgen Inc. Using fucosidase to control afucosylation level of glycosylated proteins
WO2023161885A1 (en) * 2022-02-25 2023-08-31 Kashiv Biosciences, Llc A process for improving polypeptide expression in mammalian cell culture
WO2024220916A1 (en) 2023-04-20 2024-10-24 Amgen Inc. Methods of determining relative unpaired glycan content
WO2025036924A1 (en) * 2023-08-16 2025-02-20 Glaxosmithkline Intellectual Property Limited Method of controlling antibody glycosylation profile

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6936694B1 (en) 1982-05-06 2005-08-30 Intermune, Inc. Manufacture and expression of large structural genes
AU588819B2 (en) 1984-10-29 1989-09-28 Immunex Corporation Cloning of human granulocyte-macrophage colony stimulating factor gene
US4968607A (en) 1987-11-25 1990-11-06 Immunex Corporation Interleukin-1 receptors
US5075222A (en) 1988-05-27 1991-12-24 Synergen, Inc. Interleukin-1 inhibitors
US6048728A (en) 1988-09-23 2000-04-11 Chiron Corporation Cell culture medium for enhanced cell growth, culture longevity, and product expression
WO1990005183A1 (en) 1988-10-31 1990-05-17 Immunex Corporation Interleukin-4 receptors
US5395760A (en) 1989-09-05 1995-03-07 Immunex Corporation DNA encoding tumor necrosis factor-α and -β receptors
DK0939121T4 (en) 1989-09-12 2008-02-04 Ahp Mfg B V TNF-binding proteins
US6204363B1 (en) 1989-10-16 2001-03-20 Amgen Inc. Stem cell factor
US5272064A (en) 1989-12-19 1993-12-21 Amgen Inc. DNA molecules encoding platelet-derived growth factor B chain analogs and method for expression thereof
US5149792A (en) 1989-12-19 1992-09-22 Amgen Inc. Platelet-derived growth factor B chain analogs
US5096816A (en) 1990-06-05 1992-03-17 Cetus Corporation In vitro management of ammonia's effect on glycosylation of cell products through pH control
WO1991018982A1 (en) 1990-06-05 1991-12-12 Immunex Corporation Type ii interleukin-1 receptors
US5350683A (en) 1990-06-05 1994-09-27 Immunex Corporation DNA encoding type II interleukin-1 receptors
US6284471B1 (en) * 1991-03-18 2001-09-04 New York University Medical Center Anti-TNFa antibodies and assays employing anti-TNFa antibodies
DK0672141T3 (en) 1992-10-23 2003-06-10 Immunex Corp Methods for Preparation of Soluble Oligomeric Proteins
US5554512A (en) 1993-05-24 1996-09-10 Immunex Corporation Ligands for flt3 receptors
US5981713A (en) 1994-10-13 1999-11-09 Applied Research Systems Ars Holding N.V. Antibodies to intereleukin-1 antagonists
US5721121A (en) 1995-06-06 1998-02-24 Genentech, Inc. Mammalian cell culture process for producing a tumor necrosis factor receptor immunoglobulin chimeric protein
CA2225378C (en) 1995-06-29 2012-04-17 Immunex Corporation Cytokine that induces apoptosis
US6613544B1 (en) 1995-12-22 2003-09-02 Amgen Inc. Osteoprotegerin
US6096728A (en) 1996-02-09 2000-08-01 Amgen Inc. Composition and method for treating inflammatory diseases
US6271349B1 (en) 1996-12-23 2001-08-07 Immunex Corporation Receptor activator of NF-κB
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
US6337072B1 (en) 1998-04-03 2002-01-08 Hyseq, Inc. Interleukin-1 receptor antagonist and recombinant production thereof
US6528286B1 (en) 1998-05-29 2003-03-04 Genentech, Inc. Mammalian cell culture process for producing glycoproteins
JP2001120262A (en) 1999-10-26 2001-05-08 Welfide Corp Method for enhancing production of physiologically active substance
WO2001036637A1 (en) 1999-11-17 2001-05-25 Immunex Corporation Receptor activator of nf-kappa b
US6544424B1 (en) 1999-12-03 2003-04-08 Refined Technology Company Fluid filtration system
CN1309735C (en) 2000-05-26 2007-04-11 布里斯托尔-迈尔斯斯奎布公司 Soluble CTL A4 mutant molecules and use thereof
CA2481658A1 (en) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Method of enhancing of binding activity of antibody composition to fcy receptor iiia
DE10312765A1 (en) 2003-03-21 2004-09-30 Bayer Technology Services Gmbh Continuous method for sterilization and, if required, virus inactivation of fluid, in particular, aqueous reaction media involves combined heat treatment and ultraviolet irradiation of the reaction medium
US7294484B2 (en) 2004-08-27 2007-11-13 Wyeth Research Ireland Limited Production of polypeptides
TWI364458B (en) 2004-08-27 2012-05-21 Wyeth Res Ireland Ltd Production of tnfr-lg
US8053238B2 (en) 2005-10-31 2011-11-08 Unhwa Corporation Isolated population of plant single cells and method of preparing the same
US20070231895A1 (en) 2005-11-02 2007-10-04 Lee Gene W Methods for adapting mammalian cells
EP3026109B1 (en) 2005-12-08 2022-03-09 Amgen Inc. Improved production of glycoproteins using manganese
WO2007081031A1 (en) * 2006-01-16 2007-07-19 Hokkaido University Glycosyltransferase inhibitor
US20100166741A1 (en) * 2006-07-13 2010-07-01 Genentech , Inc. Altered br-3 binding polypeptides
KR101495549B1 (en) 2006-07-13 2015-02-25 와이어쓰 엘엘씨 Production of glycoproteins
FR2904558B1 (en) * 2006-08-01 2008-10-17 Lab Francais Du Fractionnement "RECOMBINANT OR TRANSGENIC FACTOR VII COMPOSITION, MAJORITYALLY HAVING BIANTENNAE, BISIALYLATED AND NON-FUCOSYLATED GLYCANNIC FORMS"
EP2395077A1 (en) 2006-11-03 2011-12-14 Wyeth LLC Glycolysis-inhibiting substances in cell culture
PT2115126E (en) 2007-03-02 2015-08-24 Wyeth Llc Use of copper and glutamate in cell culture for production of polypeptides
CA2682472A1 (en) * 2007-03-30 2008-10-09 Centocor Ortho Biotech Inc. High expression clones of mammalian cells with fluorescent protein a or g
EP2137655B1 (en) 2007-04-16 2012-07-11 Momenta Pharmaceuticals, Inc. Defined glycoprotein products and related methods
WO2008154014A2 (en) 2007-06-11 2008-12-18 Amgen Inc. A method for culturing mammalian cells to improve recombinant protein production
DK2173861T4 (en) 2007-06-15 2017-05-15 Amgen Inc Methods for treating a cell culture medium for use in a bioreactor
WO2010141855A1 (en) 2009-06-05 2010-12-09 Momenta Pharmaceuticals, Inc. Methods of modulating fucosylation of glycoproteins
WO2012054654A2 (en) 2010-10-20 2012-04-26 Morphotek, Inc. Anti-folate receptor alpha antibody glycoforms
EP2678423A1 (en) 2011-02-23 2014-01-01 Amgen Inc. Cell culture media for uvc exposure and methods related thereto
MX346663B (en) * 2011-03-06 2017-03-27 Merck Serono Sa Low fucose cell lines and uses thereof.
US9133493B2 (en) 2011-04-21 2015-09-15 Amgen Inc. Method for culturing mammalian cells to improve recombinant protein production
EP2702077A2 (en) 2011-04-27 2014-03-05 AbbVie Inc. Methods for controlling the galactosylation profile of recombinantly-expressed proteins
CA2952347A1 (en) 2011-07-01 2013-01-10 Amgen Inc. Mammalian cell culture
AR087433A1 (en) * 2011-08-08 2014-03-26 Merck Sharp & Dohme N-GLICOSILATED INSULIN ANALOGS
EA201490502A1 (en) 2011-09-16 2014-06-30 Амген Инк. PRE-PROGRAMMED CONTINUOUS FOOD OF CULTURES OF CELLS WITHOUT FEEDBACK CONTROL
AU2012328753A1 (en) 2011-10-26 2014-04-24 Amgen Inc. Methods of reducing or eliminating protein modification and degradation arising from exposure to UV light
US20150119558A1 (en) * 2012-01-20 2015-04-30 Agency For Science, Technology And Research Cho-gmt recombinant protein expression
WO2013114164A1 (en) * 2012-01-30 2013-08-08 Dr. Reddy's Laboratories Limited Method for obtaining glycoprotein composition with increased afucosylation content
EP2809773B1 (en) * 2012-01-30 2020-09-02 Dr. Reddy's Laboratories Limited Process of modulating man5 and/or afucosylation content of glycoprotein composition
WO2013138159A1 (en) 2012-03-15 2013-09-19 Amgen Inc. Methods of determining exposure to uv light
US10481164B2 (en) 2012-03-26 2019-11-19 Amgen Inc. Method for using light scattering in real time to directly monitor and control impurity removal in purification processes
EP2905290B1 (en) * 2012-10-05 2019-12-04 Kyowa Kirin Co., Ltd. Heterodimeric protein composition
US9677105B2 (en) 2013-03-14 2017-06-13 Momenta Pharmaceuticals, Inc. Methods of cell culture
US8956830B2 (en) 2013-03-14 2015-02-17 Momenta Pharmaceuticals, Inc. Methods of cell culture
NZ716182A (en) 2013-07-23 2018-07-27 Biocon Ltd Methods for controlling fucosylation levels in proteins
SG11201606856SA (en) * 2014-02-27 2016-09-29 Hoffmann La Roche Modulation of cell growth and glycosylation in recombinant glycoprotein production
EP3215604A4 (en) * 2014-10-27 2018-07-25 Agency For Science, Technology And Research Methods of recombinant protein expression in a cell comprising reduced udp-galactose transporter activity
AU2015355087B2 (en) 2014-12-01 2020-04-09 Amgen Inc. Process for manipulating the level of glycan content of a glycoprotein

Also Published As

Publication number Publication date
JP7066775B2 (en) 2022-05-13
US10167492B2 (en) 2019-01-01
KR20170083636A (en) 2017-07-18
WO2016089919A1 (en) 2016-06-09
HUE049201T2 (en) 2020-09-28
AU2022200586A1 (en) 2022-02-24
US20190085370A1 (en) 2019-03-21
EP3227454A1 (en) 2017-10-11
BR112017011652A2 (en) 2018-06-26
EA036178B1 (en) 2020-10-09
US20200172947A1 (en) 2020-06-04
CY1123247T1 (en) 2021-10-29
AU2020202302A1 (en) 2020-04-23
EA202091598A2 (en) 2020-10-30
JP2022101669A (en) 2022-07-06
SG11201704351WA (en) 2017-06-29
US20170362625A1 (en) 2017-12-21
JP2024095777A (en) 2024-07-10
US20230159974A1 (en) 2023-05-25
LT3227454T (en) 2020-07-27
AU2024204313A1 (en) 2024-07-11
JP6698681B2 (en) 2020-05-27
ZA202006002B (en) 2022-03-30
IL252569A0 (en) 2017-07-31
DK3227454T3 (en) 2020-04-14
SI3227454T1 (en) 2020-06-30
US20210017565A1 (en) 2021-01-21
PT3227454T (en) 2020-04-06
MX385409B (en) 2025-03-04
CA2969225A1 (en) 2016-06-09
AU2015355087A1 (en) 2017-06-29
EP3680344A1 (en) 2020-07-15
ZA201703729B (en) 2021-03-31
EA201791223A1 (en) 2017-10-31
ES2784503T3 (en) 2020-09-28
KR102623965B1 (en) 2024-01-11
IL276165B (en) 2022-11-01
EP3227454B1 (en) 2020-01-29
MX2017006997A (en) 2017-10-16
IL276165A (en) 2020-09-30
JP2017538446A (en) 2017-12-28
PL3227454T3 (en) 2020-07-27
EA202091598A3 (en) 2021-01-29
CN107109455B (en) 2022-02-18
US10822630B2 (en) 2020-11-03
JP2020124216A (en) 2020-08-20
AU2015355087B2 (en) 2020-04-09
IL252569B (en) 2020-08-31
CN107109455A (en) 2017-08-29
CA2969225C (en) 2023-08-22
CL2017001369A1 (en) 2018-02-23

Similar Documents

Publication Publication Date Title
ZA202006002B (en) Process for manipulating the level of glycan content of a glycoprotein
GB201413701D0 (en) Process
GB201417076D0 (en) Process
GB201405800D0 (en) Process
GB201405210D0 (en) Process
GB201406890D0 (en) Process
GB201404468D0 (en) Process
SG11201701502VA (en) A process for the production of adenovirus
GB201415862D0 (en) Process
GB201402950D0 (en) Process
GB2522599B (en) Process for separating materials
GB201402782D0 (en) Process
GB201400137D0 (en) Process
GB201412406D0 (en) Process
SG11201704523WA (en) A process for the manufacture of idalopirdine
GB201414292D0 (en) Process
GB201411627D0 (en) Process
GB201415972D0 (en) Process
GB201412656D0 (en) Process
GB201405209D0 (en) Process
GB201411623D0 (en) Process
GB201405929D0 (en) Process
GB201403057D0 (en) Process
IL252471A0 (en) A process for the manufacture of idalopirdine
SG11201703297QA (en) Separation process